Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells.

ABSTRACT:

Introduction

Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase exhibiting high affinity for reduced folate carrier-1 with antineoplastic and immunosuppressive activities, similar to methotrexate. Despite advances in multi-modality treatment strategies, the survival rates for children with high-risk neuroblastoma have failed to improve. Therefore, the intense research continues in order to identify the ideal novel agent or combination of chemotherapy drugs to treat high-risk neuroblastoma.

Materials and methods

Four human neuroblastoma cell lines were used to determine IC₅₀ values of select chemotherapy agents. Antiproliferative effects of pralatrexate were assessed by adherent and non-adherent colony formation assays. Cell cycle arrest and apo

SUBMITTER: Clark RA 

PROVIDER: S-EPMC7429182 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature